Sclerostin mAntibody to Treat Periodontal Disease

Clinical Need

Periodontitis is known to affect approximately 50% of the U.S. adult population, with approximately 10% of patients afflicted with severe form of the disease leading to tooth loss. Although various procedures have been explored for the regeneration of the periodontium and bone, predictable treatments to arrest and rebuild lost tissues around teeth and/or tooth-replacing dental implants are limited, and to date, there are no FDA-approved bone anabolic agents available to treat periodontal or peri-implant bone loss.

Solution

A team of researchers led by Dr. William Giannobile at the University of Michigan, is developing a systemic and local delivery of sclerostin monoclonal antibody to restore lost periodontium or implant-supporting alveolar bone. The approach offers the potential for easy dosing of sclerostin antibody to regenerate lost periodontium or improve peri-implant bone density.

Competitive Advantage

By taking advantage of easy delivery of sclerostin monoclonal antibody, which is already being clinically explored for improvement of bone density in other indications such as osteoporosis, this approach may represent an improved access to drug therapies for periodontal and dental implant-related diseases that might otherwise not be as available due to limited reimbursement through typical dental insurance.

How the ITP Program Supports this Project

The work supported by the ITP program is focused on the IND submission for the design of a phase I/II human clinical trial to use systemic sclerostin antibody delivery to treat periodontal disease.

Clinical Translation Pathway

Publications:


Intellectual Property:


Commercialization Strategy:

In development with the MPWRM Commercialization/Market Needs Core

Regulatory Pathway:

In development with the MPWRM Regulatory Core

Product Launch Strategy:

In development with the MPWRM Commercialization/Market Needs Core

Contact Information:

Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center www.doctrc.com

Mutsumi Yoshida, PhD
Managing Director, U-M site
yoshidam@umich.edu
(734) 764-4622

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.